Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | PRKACG | P22612 | 1/20 | 0.38 |
| ▸ | PRKACB | P22694 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3689406 | 0.86 | PGR (0.38) | GAAMEN1KMT2ACNR2 | |
| SCHEMBL3699074 | 0.83 | CMA1 (0.45) | ALDH1A1KDM4E | |
| SCHEMBL3699071 | 0.83 | CMA1 (0.45) | ALDH1A1KDM4E | |
| SCHEMBL13822648 | 0.81 | FABP4 (0.42) | ALDH1A1SMN1; SMN2CYP2D6CNR2HDAC1 | |
| SCHEMBL2317387 | 0.80 | ALDH1A1 (0.38) | ALDH1A1CNR2KDM4E | |
| SCHEMBL3686184 | 0.77 | ACACB (0.35) | ALDH1A1 | |
| SCHEMBL3686182 | 0.76 | CMA1 (0.38) | GAA | |
| SCHEMBL3685071 | 0.75 | ALDH1A1 (0.40) | ALDH1A1TSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3695212 | 0.75 | CMA1 (0.35) | GAAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3683080 | 0.75 | CMA1 (0.35) | GAAALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377949-B2 | Quinazolinedione chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-19 | — | — | US | disclosed |
| EP-2188277-B1 | QUINAZOLINEDIONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-20120122863-A1 | Quinazolinedione Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122863-A1 | Quinazolinedione Chymase Inhibitors | CMA1, CTSC, TPSG1 | GAA 26/4885ALDH1A1 2108/4885TSHR 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.